Document Detail


Acquired hemophilia: a single-center survey with emphasis on immunotherapy and treatment-related side-effects.
MedLine Citation:
PMID:  12406009     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Acquired hemophilia is a rare disease caused by the development of autoantibodies against factor VIII. Since 1981 we have observed 17 patients with this disorder in our institution. The objective of this survey was to assess the epidemiological features, clinical course, and mortality rate of these patients, with special emphasis on therapy-related side-effects. Also, we present our results with an immunosuppressive approach based on the severity of bleeding episodes. METHODS: Clinical records of all patients with acquired hemophilia due to factor VIII inhibitor admitted or referred to our hospital between 1981 and 2001 were reviewed retrospectively. We collected each patient's sex, age, medical history, presenting symptoms, activated partial thromboplastin time, factor VIII activity, and inhibitor titre. Patient's clinical courses, including their bleeding episodes, response to therapy, and therapy-related side-effects, were also recorded. RESULTS: Complete and partial responses were achieved in 14 and one patient, respectively (overall response rate 88%) after a median time to complete response of 3.5 months (range 30 d - 25 months). The inhibitor-related and overall mortality rates were 12% and 29%, respectively. Side-effects were frequent: two patients had blood-borne infections, three patients had thrombotic complications, and nine patients had immunosuppressive therapy-related side-effects. In five patients, discontinuation of cyclophosphamide or prednisone was required. CONCLUSIONS: Although our response rates were remarkable, this survey showed that treatment-related morbidity could also be very important. Therefore, it is pertinent to bear in mind these potential side-effects in order to decide the most appropriate therapy for each particular patient.
Authors:
Julio Delgado; Ana Villar; Victor Jimenez-Yuste; Jose Gago; Manuel Quintana; Fernando Hernandez-Navarro
Related Documents :
12366499 - The prognostic value of global haemostatic tests in the intensive care unit setting.
21172929 - Retinal vascular calibre is altered in patients with rheumatoid arthritis: a biomarker ...
21406459 - Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value ...
11460009 - Maximal endothelial tissue plasminogen activator release is not impaired in patients wi...
21288959 - Remission is the goal for cardiovascular risk management in patients with rheumatoid ar...
6424339 - 1-deamino-8-d-arginine-vasopressin--an alternative in the management of mild haemophili...
3101479 - Changes of plasma levels of apolipoproteins a-i, a-ii, and b and their isoforms in pati...
22618889 - Comparison of diagnostic accuracy between three different rules of interpreting high se...
24398089 - The clinical spectrum of microcystic macular oedema.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of haematology     Volume:  69     ISSN:  0902-4441     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-10-30     Completed Date:  2002-12-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  158-64     Citation Subset:  IM    
Affiliation:
Department of Hematology, Hospital Universitario La Paz, Madrid, Spain. jdelgon@terra.ed
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Autoantibodies / immunology
Autoimmune Diseases / immunology,  therapy
Child
Factor VIII / immunology*
Female
Hemophilia A / etiology,  immunology,  mortality,  therapy*
Humans
Immunosuppressive Agents / adverse effects,  therapeutic use*
Immunotherapy*
Male
Middle Aged
Retrospective Studies
Survival Analysis
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Immunosuppressive Agents; 9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of reticulated platelet count and mean platelet volume determination in the evaluation of...
Next Document:  Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome?